Clinical Trial Design: Bayesian and Frequentist Adaptive Methods

Clinical Trial Design: Bayesian and Frequentist Adaptive Methods

Volumn , Issue , 2012, Pages

  Yin, Guosheng ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84891583364     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118183335     Document Type: Book

References (268)

1. Abdelbasit, K. M. and Plackett, R. L. (1982). Experimental design for joint action. Biometrics 38, 171-179.
2. Akaike, H. (1973). Information theory and an extension of the maximum likelihood principle. In: Second International Symposium on Information Theory, B. N. Petrov and F. Csaki (eds.), pp. 267-281. Budapest: Akademiai Kiado.
3. Albert, J. H. and Chib, S. (1993). Bayesian analysis of binary and polychotomous response data. Journal of the American Statistical Association 88, 669-679.
4. Andersen, P. K. and Gill, R. D. (1982). Cox's regression model for counting processes: A large-sample study. The Annals of Statistics 10, 1100-1120.
5. Angrist, J. D., Imbens, G. W., and Rubin, D. B. (1996). Identification of causal effects using instrumental variables (with discussion). Journal of the American Statistical Association 91,444-472.
6. Antognini, A. B. and Giovagnoli, A. (2004). A new biased coin design for the sequential allocation of two treatments. Journal of the Royal Statistical Society, Series C 53, 651-664.
7. Ashford, J. R. (1981). General models for the joint action of mixtures of drugs. Biometrics 37, 457-474.
8. Babb, J., Rogatko, A., and Zacks, S. (1998). Cancer phase I clinical trials: Efficient dose escalation with overdose control. Statistics in Medicine 17, 1103-1120.
9. Bang, H. and Davis, C. E. (2007). On estimating treatment effects under noncompliance in randomized clinical trials: Are intent-to-treat or instrumental variables analyses perfect solutions? Statistics in Medicine 26, 954-964.
10. Barker, A. D., Sigman, C. C, Kelloff, G. J., Hylton, N. M., Berry, D. A., and Esserman, L. J. (2009). I-SPY 2: An adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clinical Pharmacology & Therapeutics 86,97-100.
11. Barlow, R. E., Bartholomew, D. J., Bremner, J. M., and Brunk, H. D. (1972). Statistical Inference under Order Restrictions: The Theory and Application of Isotonic Regression. New York: Wiley.
12. Bather, J. A. (1981). Randomized allocation of treatments in sequential medical trials (with discussion). Journal of the Royal Statistical Society, Series B 43,265-292.
13. Bather, J. A. (1985). On the allocation of treatments in sequential medical trials (with discussion). International Statistical Review 53, 1-13.
14. Bauer, P. and Könne, K. (1994). Evaluation of experiments with adaptive interim analyses. Biometrics 50, 1029-1041.
15. Bekele, B. N., Ji, Y, Shen, Y, and Thall, P. F. (2008). Monitoring late-onset toxicities in phase I trials using predicted risks. Biostatistics 9, 442-457.
16. Bekele, B. N. and Shen, Y. (2005). A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trial. Biometrics 61, 343-354.
17. Berger, J. O. (1985). Statistical Decision Theory and Bayesian Analysis. New York: Springer-Verlag.
18. Berkson, J. and Gage, R. P. (1952). Survival curve for cancer patients following treatment. Journal of the American Statistical Association 47, 501-515.
19. Berry, D. A. (2006). Bayesian clinical trials. Nature Reviews Drug Discovery 5, 27-36.
20. Berry, D. A. (2011). Adaptive clinical trials: The promise and the caution. Journal of Clinical Oncology 29, 606-609.
21. Berry, D. A. and Eick, S. G. (1995). Adaptive assignment versus balanced randomization in clinical trials: A decision analysis. Statistics in Medicine 14, 231-246.
22. Berry, S. M., Carlin, B. P., Lee, J. J., and Müller, P. (2010). Bayesian Adaptive Methods for Clinical Trials. Chapman & Hall/CRC, Boca Raton.
23. Biswas, S., Liu, D. D., Lee, J. J., and Berry, D. A. (2009). Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center. Clinical Trials 6, 205-216.
24. Biswas, A. and Mandai, S. (2004). Optimal adaptive designs in phase III clinical trials for continuous responses with covariates. In: Advances in Model-Oriented Design and Analysis-mODa 7, A. D. Bucchianico, H. Läuter, and H. P. Wynn (eds.), pp. 51-59. Heidelberg: Physica-Verlag.
25. Blackwell, D. H. and Hodges, J. L. (1957). Design for the control of selection bias. Annals of Mathematical Statistics 28,449-460.
26. Bliss, C. I. (1939). The toxicity of poisons applied jointly. Annals of Applied Biology 26, 585-615.
27. Braun, T. M. (2002). The bivariate continual reassessment method: extending the CRM to phase I trials of two competing outcomes. Controlled Clinical Trials 23, 240-256.
28. Braun, T. M. (2006). Generalizing the TITE-CRM to adapt for early-and late-onset toxicities. Statistics in Medicine 25, 2071-2083.
29. Braun, T. M., Thall, P. F., Nguyen, H., and de Lima, M. (2007). Simultaneously optimizing dose and schedule of a new cytotoxic agent. Clinical Trials 4, 113-124.
30. Braun, T. M. and Wang, S. (2010). A hierarchical Bayesian design for phase I trials of novel combinations of cancer therapeutic agents. Biometrics 66, 805-812.
31. Braun, T. M., Yuan, Z., and Thall, P. F. (2005). Determining a maximum tolerated schedule of a cytotoxic agent. Biometrics 61, 335-343.
32. Breslow, N. E. (1974). Contribution to the discussion of the paper by D. R. Cox. Journal of the Royal Statistical Society, Series B 34, 187-220.
33. Buckland, S. T., Burnham, K. P., and Augustin, N. H. (1997). Model selection: An integral part of inference. Biometrics 53,603-618.
34. Carlin, B. P. and Louis, T. (2008). Bayesian Methods for Data Analysis. 3rded. Boca Raton, FL: Chapman k Hall/CRC.
35. Casella, G. and Berger, R. L. (2001). Statistical Inference. 2nd ed. Pacific Grove, CA: Duxbury Press.
36. Chang, M. (2008). Adaptive Design Theory and Implementation Using SAS and R. Boca Raton, FL: Chapman & Hall/CRC.
37. Chang, M. N., Therneau, T. M., Wieand, H. S., and Cha, S. S. (1987). Designs for group sequential phase II clinical trials. Biometrics 43, 865-874.
38. Chen, M., Shao, Q., and Ibrahim, J. G. (2000). Monte Carlo Methods in Bayesian Computation. New York: Springer.
39. Chernozhukov, V. and Hong, H. (2003). An MCMC approach to classical estimation. Journal of Econometrics 115, 293-346.
40. Cheung, Y K. (2011). Dose Finding by the Continual Reassessment Method. Boca Raton, FL: Chapman & Hall/CRC.
41. Cheung, Y K. and Chappell, R. (2000). Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics 56, 1177-1182.
42. Chevret, S. (2006). Statistical Methods for Dose-Finding Experiments. Chichester, England: John Wiley & Sons.
43. Chow, S.-C. and Chang, M. (2006). Adaptive Design Methods in Clinical Trials. Boca Raton, FL: Chapman & Hall/CRC.
44. Chow, S.-C, Shao, J., and Chang, M. (2007). Sample Size Calculations in Clinical Research, 2nd ed. New York: Marcel Dekker.
45. Clayton, D. G. (1978). A model for association in bivariate life tables and its application in epidemiological studies of familial tendency in chronic disease incidence. Biometrika 65, 141-152.
46. Efron, B. (1971). Forcing sequential experiments to be balanced. Biometrika 58, 403-417.
47. Eick, S. G. (1988). The two-armed bandit with delayed responses. The Annals of Statistics 16, 254-264.
48. Eisele, J. R. (1994). The doubly adaptive biased coin design for sequential clinical trials. Journal of Statistical Planning and Inference 38, 249-262.
49. Eisele, J. R. and Woodroofe, M. (1995). Central limit theorems for doubly adaptive biased coin designs. The Annals of Statistics 23, 234-254.
50. Elashoff, J. D. and Reedy, T. J. (1984). Two-stage clinical trial stopping rules. Biometrics 40,791-795.
51. Estey, E. H., Shen, Y., and Thall, P. F. (2000). Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB. Blood 95, 72-77.
52. Faries, D. (1994). Practical modification of the continual reassessment methods for phase I cancer clinical trials. Journal of Biopharmaceutical Statistics 4,147-164.
53. Fisher, R. A. (1926). The arrangement of field experiments. Journal of the Ministry of Agriculture 33, 503-513.
54. Fisher, L. D. (1998). Self-designing clinical trials. Statistics in Medicine 17, 1551-1562.
55. Fisher, L. D., Dixon, D. O., Herson, J., Frankowski, R. K., Hearon, M. S., and Pearce, K. E. (1990). Intention to treat in clinical trials. In: Statistical Issues in Drug Research and Development, K. E. Pearce, ed., pp. 331-350. New York: Marcel Dekker.
56. Fleming, T. R. (1982). One-sample multiple testing procedure for phase II clinical trials. Biometrics 38, 143-151.
57. Fleming, T. R. and Harrington, D. (1991). Counting Processes and Survival Analysis. New York: John Wiley & Sons.
58. Freidlin, B., Jiang, W., and Simon, R. (2010). The cross-validated adaptive signature design. Clinical Cancer Research 16, 691-698.
59. Freidlin, B. and Simon, R. (2004). Evaluation of randomized discontinuation design. Journal of Clinical Oncology 23, 5094-5098.
60. Freidlin, B. and Simon, R. (2005). Adaptive signature design: An adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clinical Cancer Research 11, 7872-7878.
61. Friedman, L. M., Furberg, C. D., and DeMets, D. L. (1998). Fundamentals of Clinical Trials, 3rd ed. New York: Springer.
62. Gasparini, M. and Eisele, J. (2000). A curve-free method for phase I clinical trials. Biometrics 56, 609-615.
63. Gehan, E. A. (1961). The determination of the number of patients required in a follow-up trial of a new chemotherapeutic agent. Journal of Chronic Diseases 13, 346-353.
64. Gelfand, A. E. and Smith, A. F. M. (1990). Sampling-based approaches to calculating marginal densities. Journal of the American Statistical Association 85, 398-409.
65. Gelman, A., Carlin, J. B., Stern, H. S. and Rubin, D. B. (2003). Bayesian Data Analysis, 2nd ed. Boca Raton, FL: Chapman & Hall/CRC.
66. Gelman, A. and Rubin, D. B. (1992). Inference from iterative simulation using multiple sequences. Statistical Science 7,457-511.
67. Geman, S. and Geman, D. (1984). Stochastic relaxation, Gibbs distributions and the Bayesian restoration of images. IEEE Transactions on Pattern Analysis and Machine Intelligence 6, 721-741.
68. Geweke, J. (1992). Evaluating the accuracy of sampling-based approaches to the calculation of posterior moments. In: Bayesian Statistics 4, J. M. Bernardo, J. Berger, A. P. Dawid, and A. F. M. Smith (eds.), pp. 169-193. Oxford: Oxford University Press.
69. Gezmu, M. and Flournoy, N. (2006). Group up-and-down designs for dose-finding. Journal of Statistical Planning and Inference 136,1749-1764.
70. Gilks, W. R" Best, N. G., and Tan, K. K. C. (1995). Adaptive rejection Metropolis sampling within Gibbs sampling. Journal of the Royal Statistical Society, Series C 44,455-472.
71. Glasser, S. P., Salas, M., and Delzell, E. (2007). Importance and challenges of studying marketed drugs: What is a phase IV study? Common clinical research designs, registries, and self-reporting systems. The Journal of Clinical Pharmacology 47, 1074-1086.
72. Goodman, S. N., Zahurak, M. L., and Piantadosi, S. (1995). Some practical improvements in the continual reassessment method for phase I studies. Statistics in Medicine 14, 1149-1161.
73. Gooley, T. A., Martin, P. J., Fisher, L. D., and Pettinger, M. (1994). Simulation as a design tool for phase I/II clinical trial: An example from bone marrow transplantation. Controlled Clinical Trial 15,450-462.
74. Gould, A. L. (1992). Interim analyses for monitoring clinical trials that do not materially affect the type I error rate. Statistics in Medicine 11, 55-66.
75. Gould, A. L. (2001). Sample size re-estimation: recent developments and practical considerations. Statistics in Medicine 20, 2625-2643.
76. Gould, A. L. and Pecore, V. J. (1982). Group sequential methods for clinical trials allowing early acceptance of H0 and incorporating costs. Biometrika 69, 75-80.
77. Greenwood, M. (1926). The natural duration of cancer. Reports on Public Health and Medical Subjects, No. 33, His Majesty's Stationery Office.
78. Hall, A. R. (2005). Generalized Method of Moments. New York: Oxford University Press.
79. Hansen, L. P. (1982). Large sample properties of generalized method of moments estimators. Econometrica 50, 1029-1054.
80. Hansen, L. P., Heaton, J., and Yaron, A. (1996). Finite-sample properties of some alternative GMM estimators. Journal of Business & Economic Statistics 14, 262-280.
81. Harville, D. A. (1977). Maximum likelihood approaches to variance component estimation and to related problems. Journal of the American Statistical Association 72, 320-338.
82. Hastings, W. K. (1970). Monte Carlo sampling methods using Markov chains and their applications. Biometrika 57,97-109.
83. Hedaya, M. A. (2007). Basic Pharmacokinetics. Boca Raton, FL: CRC Press.
84. Heyd, J. M. and Carlin, B. P. (1999). Adaptive design improvements in the continual reassessment method for phase I studies. Statistics in Medicine 18,1307-1321.
85. Hill, A. V. (1910). The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves. The Journal of Physiology 40, iv-vii.
86. Hjort, N. L. and Claeskens, G. (2003). Frequentist model average estimators (with discussion). Journal of the American Statistical Association 98, 879-899.
87. Hochberg, Y. (1988). A sharper Bonferroni procedure for multiple tests of significance. Biometrika 75, 800-802.
88. Hoeting, J. A., Madigan, D., Raftery, A. E., and Volinsky, C. T. (1999). Bayesian model averaging: A tutorial. Statistical Science 14, 382-01.
89. Hogg, R. V., McKean, J. W., and Craig, A. T. (2005). Introduction to Mathematical Statistics. Upper Saddle River, NJ: Pearson Prentice Hall.
90. Holm, S. (1979). A simple sequentially rejective multiple test procedure. Scandinavian Journal of Statistics 6, 65-70.
91. Hougaard, P. (1986). A class of multivariate failure time distributions. Biometrika 73, 671-678.
92. Hu, F. and Rosenberger, W. F. (2003). Optimality, variability, power: Evaluating response-adaptive randomization procedures for treatment comparisons. Journal of the American Statistical Association 98, 671-678.
93. Hu, F. and Rosenberger, W. F. (2006). The Theory of Response-Adaptive Randomization in Clinical Trials. New York: Wiley.
94. Hu, F. and Zhang, L. X. (2004). Asymptotic properties of doubly adaptive biased coin designs for multitreatment clinical trials. The Annals of Statistics 32, 268-301.
95. Huang, X., Biswas, S., Oki, Y, Issa, J. P., and Berry, D. A. (2007). A parallel phase MI clinical trial design for combination therapies. Biometrics 63, 429-436.
96. Huang, Y and Hsu, J. C. (2007). Hochberg's step-up method: Cutting corners off Holm's step-down method. Biometrika 94, 965-975.
97. Hunsberger, S., Rubinstein, V. L., Dancey, J., and Korn, E. L. (2005). Dose escalation trial designs based on a molecularly targeted endpoint. Statistics in Medicine 24, 2171-2181.
98. Ibrahim, J. G., Chen, M., and Sinha, D. (2001). Bayesian Survival Analysis. New York: Springer.
99. Inoue, L. Y T., Thall, P. F, and Berry, D. A. (2002). Seamlessly expanding a randomized phase II trial to phase III. Biometrics 58, 823-831.
100. Ishizuka, N. and Ohashi, Y. (2001). The continual reassessment method and its applications: A Bayesian methodology for phase I cancer clinical trials. Statistics in Medicine 20, 2661-2681.
101. Ivanova, A. (2003). A play-the-winner type urn model with reduced variability. Metrika 58,1-13.
102. Jeffreys, H. (1961), Theory of Probability, 3rd ed. London: Oxford University Press.
103. Jennison, C. and Tumbull, B. W. (1989). Interim analyses: The repeated confidence interval approach (with discussion). Journal of the Royal Statistical Society, Series B 51, 305-361.
104. Jennison, C. and Tumbull, B. W. (1997). Group-sequential analysis incorporating covariate information. Journal of the American Statistical Association 92,1330-1341.
105. Jennison, C. and Tumbull, B. W. (2000). Group Sequential Methods with Applications to Clinical Trials. Boca Raton, FL: Chapman & Hall/CRC.
106. Ji, Y. and Bekele, B. N. (2009). Adaptive randomization for multi-arm comparative clinical trials based on joint efficacy/toxicity outcomes. Biometrics 65, 876-884.
107. Ji, Y, Li, Y, and Bekele, B. N. (2007). Dose-finding in phase I clinical trials based on toxicity probability intervals. Clinical Trials 4, 235-244.
108. Ji, Y, Li, Y, and Yin, G. (2007). Bayesian dose finding in phase I clinical trials based on a new statistical framework. Statistica Sinica 17, 531-547.
109. Jiang, W., Freidlin, B., and Simon, R. (2007). Biomarker-adaptive threshold design: A procedure for evaluating treatment with possible biomarker-defined subset effect. Journal of National Cancer Institute 99, 1036-1043.
110. Julious, S. A. (2010). Sample Sizes for Clinical Trials. Boca Raton, FL: Chapman & Hall/CRC.
111. Kalbfleisch, J. D. and Prentice, R. L. (2002). The Statistical Analysis of Failure Time Data, 2nd ed. New York: John Wiley.
112. Kaplan, E. L. and Meier, P. (1958). Non-parametric estimation from incomplete observations. Journal of the American Statistical Association 53,457-481.
113. Kass, R. E. and Raftery, A. E. (1995). Bayes factors. Journal of the American Statistical Association 90, 773-795.
114. Kelly, J. A., Spielberg, F, and McAuliffe, T. L. (2008). Defining, designing, implementing, and evaluating phase 4 HIV prevention effectiveness trials for vulnerable populations. Journal of Acquired Immune Deficiency Syndromes 47, 28-33.
115. Kim, J.-Y. (2002). Limited information likelihood and Bayesian analysis. Journal of Econometrics 107, 175-193.
116. Kopec, J. A., Abrahamowicz, M., and Esdaile, J. M. (1993). Randomized discontinuation trials: Utility and efficiency. Journal of Clinical Epidemiology 46, 959-971.
117. Kom, E. L. (2004). Nontoxicity endpoints in phase I trial designs for targeted, noncytotoxic agents. Journal of the National Cancer Institute 96, 977-978.
118. Korn, E. L. and Freidlin, B. (2011) Outcome-adaptive randomization: Is it useful? Journal of Clinical Oncology 29, 771-776.
119. Korn, E. L. and Simon, R. (1993). Using the tolerable-dose diagram in the design of Phase I combination chemotherapy trials. Journal of Clinical Oncology 11, 794-801.
120. Korn, E. L., Arbuck, S. G., Pluda, J. M., Simon, R., Kaplan, R. S., and Christian, M. C. (2001). Clinical trial designs for cytostatic agents: Are new approaches needed? Journal of Clinical Oncology 19, 265-272.
121. Kramar, A., Lebecq, A., and Candalh, E. (1999). Continual reassessment methods in phase I trials of the combination of two drugs in oncology. Statistics in Medicine 18,1849-1864.
122. Kuk, A. Y. C. and Chen, C. H. (1992). A mixture model combining logistic regression with proportional hazards regression. Biometrika 79, 531-541.
123. Kuzuya, K., Ishikawa, H., Nakanishi, T., et al. (2001). Optimal doses of paclitaxel and carboplatin combination chemotherapy for ovarian cancer: A phase I modified continual reassessment method study. International Journal of Clinical Oncology 6,271-278.
124. Lachin, J. M. and Foulkes, M. A. (1986). Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics 42, 507-519.
125. Lakatos, E. (1988). Sample sizes based on the log-rank statistic in complex clinical trials. Biometrics 44, 229-241.
126. Lan, K. K. G. and DeMets, D. L. (1983). Discrete sequential boundaries for clinical trials. Biometrika 70, 659-663.
127. Lee, J. J., Gu, X., and Liu, S. (2010). Bayesian adaptive randomization designs for targeted agent development. 7, 584-596.
128. Lee, J. J., Kong, M., Ayers, G. D., and Lotan, R. (2007). Interaction index and different methods for determining drug interaction in combination therapy. Journal of Biopharmaceutical Statistics 17,461-180.
129. Lee, J. J. and Liu, D. D. (2008). A predictive probability design for phase II cancer clinical trials Clinical Trials 5, 93-106.
130. Lehmacher, W. and Wassmer, G. (1999). Adaptive sample size calculations in group sequential trials. Biometrics 55, 1286-1290.
131. Lei, X., Yuan, Y, and Yin, G. (2011). Bayesian phase II clinical trial design with time-to-event adaptive randomization. Lifetime Data Analysis 17, 156-174.
132. Leung, D. H.-Y and Wang, Y.-G. (2002). An extension of the continual reassessment method using decision theory. Statistics in Medicine 21, 51-63.
133. Li, Y, Bekele, B. N., Ji, Y, and Cook, J. D. (2008). Dose-schedule finding in phase I/II clinical trials using a Bayesian isotonic transformation. Statistics in Medicine 27,4895-4913.
134. Liang, K. Y and Zeger, S. L. (1986). Longitudinal data analysis using generalized linear models. Biometrika 73,13-22.
135. Lin, Y. and Shih, W. J. (2001). Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials. Biostatistics 2, 203-215.
136. Lind, J. (1753). A Treatise of the Scurvy. Edinburgh: Sands, Murray, Cochran. Reprinted in Lind's Treatise on Scurvy, C. P. Stewart and D. Guthrie, eds. Edinburgh: Edinburgh University Press.
137. Lindley, D. V. and Phillips, L. D. (1976). Inference for a Bernoulli process (a Bayesian view). American Statistician 30, 112-119.
138. Little, R. J. A. and Rubin, D. B. (2002). Statistical Analysis with Missing Data, 2nd ed. New York: Wiley.
139. Liu, A., Shih, W. J., and Gehan, E. A. (2002). Sample size and power determination for clustered repeated measurements. Statistics in Medicine 21, 1787-1801.
140. Liu, G. and Liang, K. Y. (1997). Sample size calculations for studies with correlated observations. Biometrics 53, 937-947.
141. Liu, Q. and Chi, G. Y. H. (2001). On sample size and inference for two-stage adaptive designs. Biometrics 57, 172-177.
142. Liu, Q. and Pledger, G. W. (2005). Phase 2 and 3 combination designs to accelerate drug development. Journal of the American Statistical Association 100,493-502.
143. Loewe, S. (1953). The problem of synergism and antagonism of combined drugs. Arzeim Forsch 3, 285-290.
144. Lokich, J. (2001). Phase I clinical trial of weekly combined topotecan and irinotecan. American Journal Clinical Oncology 24, 336-340.
145. Louis, T. A. (1977). Sequential allocation in clinical trials comparing two exponential survival curves. Biometrics 33, 627-634.
146. Madigan, D. and Raftery, A. E. (1994). Model selection and accounting for model uncertainty in graphical models using Occam's window. Journal of the American Statistical Association 89, 1535-1546.
147. Mailer, R. A. and Zhou, X. (1996). Survival Analysis with Long-Term Survivors. New York: Wiley.
148. Mandrekar, S. J. and Sargent, D. J. (2009). Clinical trial designs for predictive biomarker validation: Theoretical considerations and practical challenges. Journal of Clinical Oncology 27, 4027-4034.
149. Marcus, R., Peritz, E., and Gabriel, K. R. (1976). On closed testing procedures with special reference to ordered analysis of variance. Biometrika 63, 655-660.
150. Mauguen, A., Le Deleya, M. C, and Zohar, S. (2011). Dose-finding approach for dose escalation with overdose control considering incomplete observations. Statistics in Medicine 20, 1584-1594.
151. McCullagh, P. (1983). Quasi-likelihood function. The Annals of Statistics 11, 59-67.
152. McCullagh, P. and Neider, J. A. (1989). Generalized Linear Models, 2nd ed. London: Chapman & Hall.
153. Medical Research Council. (1948). Streptomycin treatment of pulmonary tuberculosis. British Medical Journal 2, 769-782.
154. Melfi, V., Page, C, and Geraldes, M. (2001). An adaptive randomized design with application to estimation. Canadian Journal of Statistics 29,107-116.
155. Metropolis, N., Rosenbluth, A. W., Rosenbluth, M. N., Teller, A. H., and Teller, E. (1953). Equations of state calculations by fast computing machines. Journal of Chemical Physics 21, 1087-1092.
156. Mok, T. S., Wu, Y.-L., Thongprasert, S., et al. (2009). Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. The New England Journal of Medicine 361,947-957.
157. M0ller, S. (1995). An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses. Statistics in Medicine 14, 911-922.
158. Morgan, B. J. T. (1992). Analysis of Quantal Response Data. London: Chapman h Hall.
159. Moyé, L. A. (2003) Multiple Analyses in Clinical Trials: Fundamentals for Investigators. New York: Springer-Verlag.
160. Muler, J. H., McGinn, C. J., Normolle, D. Lawrence, T., Brown, D., Hejna, G., and Zalupski, M. M. (2004). Phase I trial using a time-to-event continual reassessment strategy for dose escalation of cisplatin combined with gemcitabine and radiation therapy in pancreatic cancer. Journal of Clinical Oncology 22,238-243.
161. Müller, H.-H. and Schäfer, H. (2001). Adaptive group sequential designs for clinical trials: Combining the advantages of adaptive and of classical group sequential approaches. Biometrics 57, 886-891.
162. Murtaugh, P. A. and Fisher, L. D. (1990). Bivariate binary models of efficacy and toxicity in dose-ranging trials. Communications in Statistics, Theory and Methods 19, 2003-2020.
163. Nelsen, R. B. (1999). An Introduction to Copulas. New York: Springer-Verlag.
164. Ning, J. and Huang, X. (2010). Response-adaptive randomization for clinical trials with adjustment for covariate imbalance. Statistics in Medicine 29,1761-1768.
165. O'Brien, P. C. and Fleming, T. R. (1979). A multiple testing procedure for clinical trials. Biometrics 35, 549-556.
166. O'Quigley, J. and Chevret, S. (1991). Methods for dose finding studies in cancer clinical trials: A review and results of a Monte Carlo study. Statistics in Medicine 10,1647-1664.
167. O'Quigley, J., Hughes, M. D., and Fenton, T. (2001). Dose-finding designs for HIV studies. Biometrics 57,1018-1029.
168. O'Quigley, J. and Paoletti, X. (2003). Continual reassessment method for ordered groups. Biometrics 59,430-440.
169. O'Quigley, J., Pepe, M., and Fisher, L. D. (1990). Continual reassessment method: A practical design for Phase I clinical trials in cancer. Biometrics 46, 33-8.
170. O'Quigley, J. and Shen, L. Z. (1996). Continual reassessment method: A likelihood approach. Biometrics 52, 673-684.
171. Piantadosi, S. (2005). Clinical Trials: A Methodologie Perspective. 2nd ed. New York: John Wiley & Sons.
172. Piantadosi, S., Fisher, J., and Grossman, S. (1998). Practical implementation of a modified continual reassessment method for dose finding trials. Cancer Chemotherapy and Pharmacology 41, 429-436.
173. Plackett, R. L. and Hewlett, P. S. (1967). A comparison of two approaches to the construction of models for quantal responses to mixtures of drugs. Biometrics 23, 27-44.
174. Pocock, S. J. (1977). Group sequential methods in the design and analysis of clinical trials. Biometrika 64, 191-199.
175. Pocock, S. J. and Simon, R. (1975). Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trials. Biometrics 31, 103-115.
176. Portnoy, S. (2003). Censored regression quantiles. Journal of the American Statistical Association 98, 1001-1012.
177. Posch, M. and Bauer, P. (2000). Interim analysis and sample size reassessment. Biometrics 56,1170-1176.
178. Proschan, M. A. and Hunsberger, S. A. (1995). Designed extension of studies based on conditional power. Biometrics 51, 1315-1324.
179. Raftery, A. E., Madigan, D., and Hoeting, J. A. (1997). Bayesian model averaging for linear regression models. Journal of the American Statistical Association 92, 179-191.
180. Ratain, M. J. and Sargent, D. J. (2009). Optimising the design of phase II oncology trials: the importance of randomisation. European Journal of Cancer 45, 275-280.
181. Robbins, H. (1952). Some aspects of the sequential design of experiments. Bulletin of the American Mathematical Society 58, 527-535.
182. Rochon, J. (1991). Sample size calculations for two-group repeated-measures experiments. Biometrics 47, 1383-1398.
183. Rosenberger, W. F. (1996). New directions in adaptive designs. Statistical Science 11, 137-149.
184. Rosenberger, W. F. andLachin, J. M. (2002). Randomization in Clinical Trials: Theory and Practice. New York: John Wiley & Sons.
185. Rosenberger, W. F., Stallard, N., Ivanova, A., Harper, C, and Ricks, M. (2001). Optimal adaptive designs for binary response trials. Biometrics 57, 909-913.
186. Rosner, G. L., Stadler, W., and Ratain, M. J. (2002). Randomized discontinuation design: Application to cytostatic antineoplastic agents. Journal of Clinical Oncology 20, 4478-4484.
187. Saijo, N., Takeuchi, M., and Kunitoh, H. (2009). Reasons for response differences seen in the V15-32, INTEREST and IRASS trials. Nature Reviews Clinical Oncology 6, 287-294.
188. Sargent, D. J., Conley, B. A., Allegra, C, and Collette, L. (2005). Clinical trial designs for predictive marker validation in cancer treatment trials. Journal of Clinical Oncology 23, 2020-2027.
189. Sarkar, S. (1998). Some probability inequalities for ordered MTP2 random variables: A proof of the Simes conjecture. The Annals of Statistics 26,494-504.
190. Scharfstein, D. O., Tsiatis, A. A., and Robins, J. M. (1997). Semiparametric efficiency and its implication on the design and analysis of group sequential studies. Journal of the American Statistical Association 92, 1342-1350.
191. Schoenfeld, D. (1981). The asymptotic properties of nonparametric tests for comparing survival distributions. Biometrika 68, 316-319.
192. Self, S. G. and Mauritsen, R. H. (1988). Power/sample size calculations for generalized linear models. Biometrics 44,79-86.
193. Sen, P. K. and Singer, J. M. (1993). Large Sample Methods in Statistics. New York: Chapman & Hall.
194. Sessa, C. Capri, G., Gianni, L., Peccatori, F., Grasselli, G., Bauer, J., Zucchetti, M., Vigano, L., Gatti, A., Minoia, C, Liati, P., Van den Bosch, S., Bernareggi, A. and Camboni, G., and Marsoni, S. (2000). Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex. Annals of Oncology 11, 977-983.
195. Shao, J., Yu, X., and Zhong, B. (2010). A theory for testing hypotheses under covariate-adaptive randomization. Biometrika 97, 347-360.
196. Shen, L. Z. and O'Quigley, J. (1996). Consistency of continual reassessment method under model misspecification. Biometrika 83, 395-405.
197. Shen, L. Z. and O'Quigley, J. (1996). Statistical inference for self-designing clinical trials with a one-sided hypothesis. Biometrics 55, 190-197.
198. Shih, W. J. (1992). Sample size reestimation in clinical trials. In: Biopharmaceutical Sequential Statistical Applications, pp. 285-301. New York: Marcel Dekker.
199. Shih, W. J. (2001). Sample size re-estimation-journey for a decade. Statistics in Medicine 20, 515-518.
200. Shun, Z., Yuan, W., Brady, W., and Hsu, H. (2001). Type I error in sample size re-estimations based on observed treatment difference. Statistics in Medicine 20, 497-513.
201. Simon, R. (1979). Restricted randomization in clinical trials. Biometrics 35,503-512.
202. Simon, R. (1989). Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials 10, 1-10.
203. Simon, R. (2009). Advances in clinical trial designs for predictive biomarker discovery and validation. Current Breast Cancer Reports 1, 216-221.
204. Simon, R., Freidlin, B., Rubinstein, L. V., Arbuck, S., Collins, J., and Christian, M. (1997). Accelerated titration designs for phase I clinical trials in oncology. Journal of the National Cancer Institute 89,1138-1147.
205. Storer, B. E. (1989). Design and analysis of Phase I clinical trials. Biometrics 45, 925-937.
206. Spiegelhalter, D. J., Abrams, K. R., and Myles, J. P. (2004). Bayesian Approaches to Clinical Trials and Health-Care Evaluation. England: John Wiley & Sons.
207. Spiegelhalter, D. J., Best, N. G., Carlin, B. P., and van der Linde, A. (2002). Bayesian measures of model complexity and fit. Journal of the Royal Statistical Society, Series 5 64,583-616.
208. Strom, B. L. (2006). How the US drag safety system should be changed. Journal of American Medical Association 295,2072-2074.
209. Stylianou, M. and Flournoy, N. (2002). Dose finding using the biased coin up-anddown design and isotonic regression. Biometrics 58, 171-177.
210. Sun, J. (2006). The Statistical Analysis of Interval-Censored Failure Time Data. New York: Springer.
211. Tan, M., Fang, H., Tian, G., and Houghton, P. J. (2003). Experimental design and sample size determination for testing synergism in drug combination studies based on uniform measures. Statistics in Medicine 22, 2091-2100.
212. Tanner, M. A. and Wong, W. H. (1987). The calculation of posterior distributions by data augmentation (with discussion). Journal of the American Statistical Association 82, 528-550.
213. Taves, D. R. (1974). Minimization: A new method of assigning patients to treatment and control groups. Clinical Pharmacology and Therapeutics 15,443-453.
214. Taylor, J. M. G. (1995). Semi-parametric estimation in failure time mixture models. Biometrics 51, 899-907.
215. Thall, P. F. and Cook, J. (2004). Dose-finding based on toxicity-efficacy trade-offs. Biometrics 60, 684-693.
216. Thall, P. F, Millikan, R. E., Müller, P., and Lee, S.-J. (2003). Dose-finding with two agents in phase I oncology trials. Biometrics 59, 487-496.
217. Thall, P. F. and Russell, K. E. (1998). A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials. Biometrics 54,251-264.
218. Thall, P. F. and Simon, R. (1994). Practical Bayesian guidelines for phase IIB clinical trials. Biometrics 50, 337-349.
219. Thall, P. F, Simon, R., and Estey, E. H. (1995). Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. Statistics in Medicine 14, 357-379.
220. Thall, P. F and Wathen, K. J. (2007). Practical Bayesian adaptive randomisation in clinical trials. European Journal of Cancer 43, 859-866.
221. Thompson, W. R. (1933). On the likelihood that one unknown probability exceeds another in the revises of the evidence of the two samples. Biometrika 25,275-294.
222. Therneau, T. M. (1993) How many stratification factors are "too many" to use in a randomization plan? Controlled Clinical Trials 14, 98-108.
223. Ting, N. (2006). Dose Finding in Drug Development. New York: Springer.
224. Tsiatis, A. A. and Mehta, C. (2003). On the inefficiency of the adaptive design for monitoring clinical trials. Biometrika 90, 367-378.
225. Tsodikov, A. (1998). A proportional hazards model taking account of long-term survivors. Biometrics 54, 1508-1516.
226. Vieta, E., Martinez-Aran, A., Goikolea, J. M., Torrent, C, Colom, F., Benabarre, A., and Reinares, M. (2002). A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. Journal of Clinical Psychiatry 63, 508-512.
227. Vonesh, E. F and Schork, M. A. (1986). Sample sizes in the multivariate analysis of repeated measurements. Biometrics 42,601-610.
228. Wang, H. and Wang, L. (2009). Locally weighted censored quantile regression. Journal of the American Statistical Association 104, 1117-1128.
229. Ware, J. H. and Hamel, M. B. (2011). Pragmatic trials-guides to better patient care? The New England Journal of Medicine 364,1685-1687.
230. Wassmer, G. (1998). A comparison of two methods for adaptive interim analyses in clinical trials. Biometrics 54, 696-705.
231. Wang, K. and Ivanova, A. (2005). Two-dimensional dose finding in discrete dose space. Biometrics 61, 217-222.
232. Wang, S. K. and Tsiatis, A. A. (1987). Approximately optimal one-parameter boundaries for group sequential trials. Biometrics 43,193-199.
233. Wedderburn, R. W M. (1974). Quasi-likelihood functions, generalized linear models, and the Gauss-Newton method. Biometrika 61,439-447.
234. Wei, L. J. (1978). The adaptive biased coin design for sequential experiments. The Annals of Statistics 6,92-100.
235. Wei, L. J. and Durham, S. (1978). The randomized play-the-winner rule in medical trials. Journal of the American Statistical Association 73, 840-843.
236. Whitehead, J. and Brünier, H. (1995). Bayesian decision procedures for dose determining experiments. Statistics in Medicine 14, 885-893.
237. Whitehead, J. and Stratton, I. (1983). Group sequential clinical trials with triangular continuation regions. Biometrics 39, 227-236.
238. Wilson, T. W., Lacourcière, Y., and Barnes, C. C. (1998). The antihypertensiveefficacy of losarían and amlodipine assessed with office and ambulatory blood pressure monitoring. Canadian Medical Association Journal 159,469-476.
239. Yakovlev, A. Y., Asselain, B., Bardou, V. J., Fourquet, A., Hoang, T., Rochefediere, A., and Tsodikov, A. D. (1993). A simple stochastic model of tumour recurrence and its applications to data on premenopausal breast cancer. In: Biometrie et Analyse de Dormees Spatio-Temporelles, 12, B. Asselain, M. Boniface, C. Duby, C. Lopez, J. R Masson, and J. Tranchefort, (eds.), pp. 66-82. Société Française de Biométrie, ENSA Renned, France.
240. Yin, G. (2009). Bayesian generalized method of moments (with discussion). Bayesian Analysis 4, 191-208; and Rejoinder, 217-222.
241. Yin, G., Chen, N., and Lee, J. J. (2012). Phase II trial design using Bayesian adaptive randomization and predictive probability. Journal of the Royal Statistical Society, Series C, in press.
242. Yin, G. and Ibrahim, J. (2005). Cure rate models: A unified approach. Canadian Journal of Statistics 33, 559-570.
243. Yin, G., Li, Y, and Ji, Y. (2006). Bayesian dose-finding in phase I/II trials using toxicity and efficacy odds ratio. Biometrics 62, 777-784.
244. Yin, G., Ma, Y, Liang, F., and Yuan, Y. (2011). Stochastic generalized method of moments. Journal of Computational and Graphical Statistics 20, 714-727.
245. Yin, G. and Shen, Y. (2005a). Adaptive design and estimation in randomized clinical trials with correlated observations. Biometrics 61, 362-369.
246. Yin, G. and Shen, Y. (2005b). Self-designing trial combining with classical group sequential monitoring. Journal of Biopharmaceutical Statistics 15, 667-675.
247. Yin, G. and Yuan, Y. (2009a). Bayesian model averaging continual reassessment method in phase I clinical trials. Journal of the American Statistical Association 104, 954-968.
248. Yin, G. and Yuan, Y. (2009b). Bayesian dose-finding in oncology for drug combinations by copula regression. Journal of the Royal Statistical Society, Series C 58, 211-224.
249. Yin, G. and Yuan, Y. (2009c). A latent contingency table approach to dose-finding for combinations of two agents. Biometrics 65, 866-875.
250. Yin, G. and Yuan, Y. (2010a). Bayesian approach for adaptive design. In: Handbook of Adaptive Designs in Pharmaceutical and Clinical Development, A. Pong, and S.-C. Chow, (eds.), Chapter 3. pp. (3-l)-(3-19). Boca Raton, FL: Chapman & Hall/CRC.
251. Yin, G. and Yuan, Y. (2010b). Correspondence "Bayesian dose-finding in oncology for drug combinations by copula regression" by M. Gasparini, Bailey, S. and Neuenschwander, B. Journal of Royal Statistical Society, Series C 59, 544-546.
252. Yin, G. and Zheng, S. (2011). Fractional dose-finding methods with incomplete outcomes in phase I clinical trials. Technical report, Department of Statistics and Actuarial Science at The University of Hong Kong.
253. Yuan, Y, Huang, X., and Liu, S. (2011). A Bayesian response-adaptive covariatebalanced randomization design with application to a leukemia clinical trial. Statistics in Medicine 30, 1218-1229.
254. Yuan, Y and Yin, G. (2008). Sequential continual reassessment method for twodimensional dose finding. Statistics in Medicine 27, 5664-5678.
255. Yuan, Y and Yin, G. (2009). Bayesian dose finding by jointly modeling toxicity and efficacy as time-to-event outcomes. Journal of Royal Statistical Society, Series C 58, 719-736.
256. Yuan, Y and Yin, G. (2011a). Bayesian hybrid dose-finding design in phase I oncology clinical trials. Statistics in Medicine 30,2098-2108.
257. Yuan, Y. and Yin, G. (2011b). Phase I/II adaptively randomized oncology trials with combined drugs. Annals of Applied Statistics 5, 924-942.
258. Yuan, Y and Yin, G. (2011c). On the usefulness of outcome-adaptive randomization. Journal of Clinical Oncology 29, e390-e392.
259. Yuan, Y and Yin, G. (2011d). Robust EM continual reassessment method in oncology dose finding. Journal of the American Statistical Association 106, 818-831.
260. Yuan, Z., Chappell, R., and Bailey, H. (2007). The continual reassessment method for multiple toxicity grades: A Bayesian quasi-likelihood approach. Biometrics 63, 173-179.
261. Zelen, M. (1969). Play the winner rule and the controlled clinical trial. Journal of the American Statistical Association 64, 131-146.
262. Zelen, M. and Wei, L. J. (1995). Foreword. In: Adaptive Designs. N. Flournoy and W. F. Rosenberger, (eds.), Hayward, CA: Institute of Mathematical Statistics.
263. Zellner, A. (1997). The Bayesian method of moments (BMOM): Theory and applications. Advances in Econometrics 12, 85-105.
264. Zellner, A., Tobias, J., and Ryu, H. (1997). Bayesian method of moments (BMOM) analysis of parametric and semiparametric regression models. In Proceedings of the Section on Bayesian Statistical Science, pp. 211-216. Alexandria, VA: American Statistical Association.
265. Zhang, L. and Rosenberger, W. F. (2006). Response-adaptive randomization in clinical trials with continuous outcomes. Biometrics 62, 562-569.
266. Zhang, L. and Rosenberger, W. F. (2007). Response-adaptive randomization for survival trials: the parametric approach. Journal of Royal Statistical Society, Series C 56, 153-165.
267. Zhang, L. X., Chan, W. S., Cheung, S. H., and Hu, F. (2007). A generalized dropthe-loser urn for clinical trials with delayed responses. Statistica Sinica 17, 387-409.
268. Zhou, X., Liu, S. Kim, E. S., Herbste, R. S., and Lee J. J. (2008). Bayesian adaptive design for targeted therapy development in lung cancer-a step toward personalized medicine. Clinical Trials 5, 181-193.